Switzerland's Novartis has bought the global rights to a lung cancer drug previously rejected by rival Roche, in the latest move to strengthen its oncology pipeline.
Novartis said on Thursday it would pay British biotech firm Antisoma $75 million upfront for AS1404, though total payments could reach as much as $890 million if a series of milestones are met and a second drug is acquired.
Reuters
No comments:
Post a Comment